Accel Research Sites appoints new CEO - Accel Research Sites

Create a Profile

I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.
Create a Profile
I accept digital forms of communication(Required)
Hidden
Hidden
This field is for validation purposes and should be left unchanged.

Get In Touch Mobile

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location

FIND A TRIAL NEAR YOU

No location found for this Zip Code

-- or --

No location found for this Location
Back
Date Published: 02/16/2021

Accel Research Sites appoints new CEO

Accel Research Sites today announced that Lora Parahovnik, PhD, formerly the company’s vice president of clinical operations, has been named CEO.

Parahovnik is a globally experienced leader in the Clinical Research, Clinical Affairs and Operations, Translational and Basic Research, Scientific Writing, Educational Training and Grants Submission at a world-class level. Parahovnik is a skilled Clinical Trials Expert with over seven years of experience in full cycle clinical project management including administering, directing, supervising, and coordinating multiple projects concurrently from conception to completion. She has provided multi-regional and national leadership in the execution of the scope of work, objectives, the quality of deliverables and other Clinical Operations activities directly impacting the Health Care System implications.

She joined the Accel team in March 2020, just as COVID-19 grew to global proportions, and she helped lead the Accel team in multiple clinical trials for vaccine candidates across trial sites contributing to enrollment of significant sample size for the COVID-19 vaccine trials.

As CEO, Parahovnik looks to grow connections with researchers, providers, and the community to focus on decentralized platforms and deliver high-standard patient-centered clinical research.

“The fight against COVID-19 proves just how essential clinical trials are for the good of all people and the advancement of the medical field,” Parahovnik said. “I’m incredibly proud of what the Accel Research Sites team has accomplished, and I look forward to building on our strengths as CEO.”

Parahovnik previously worked as a VP of Clinical Research with a global medical device company. She holds a Doctor of Philosophy and Master of Science degree from Technion-Israel Institute of Technology. She also earned a Bachelor of Science degree in Pharmaceutical Chemistry from Bar-Ilan University in Israel. She also serves as Adjunct Faculty in Science Department, Valencia College, East Campus, Orlando.

Accel Research Sites provides novel treatment options in all major therapeutic areas. It has more than 30 locations, including a 62-bed Phase 1 unit in Florida and units in Georgia and Alabama. Accel Research Sites has enrolled more than 12,000 patients in more than 1,000 trials since its inception in 1998.

Back

Ready to be part of healthcare history? Find the right clinical trial for you.

Get In Touch

I accept digital forms of communication(Required)
This field is for validation purposes and should be left unchanged.
Accessibility Adjustment

Color Adjustment

Orientation Adjustment

Font Size

 

Line height